Sunday 18 October 2026
Export ARCT’s income statement to Excel — free account
Arcturus Therapeutics Holdings Inc.
ARCT Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS fell 147.1% and free cash flow fell 245.7%, each against the same quarter a year earlier.
10.34
0.93
−8.25%
Follow ARCT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.50 | 4.01 | 2.05 | 5.13 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.59) | (11.29) | (10.35) | (29.22) | |
P/B ratio |
1.11 | 1.15 | 0.78 | 2.23 | |
Price to Tangible BV |
1.11 | 1.15 | 0.78 | 2.23 | |
EV/Sales |
2.56 | 1.53 | 0.15 | 3.50 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.03) | (1.43) | (0.17) | (5.85) | |
EV/FCF |
(1.03) | (1.43) | (0.17) | (5.82) | |
Quick Ratio |
5.76 | 6.19 | 6.50 | 7.68 | |
Current Ratio |
5.88 | 6.31 | 6.64 | 7.86 | |
Net Debt/EBITDA |
7.69 | 7.48 | 7.54 | 14.94 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.19 | 0.27 | 0.30 | |
Operating CF/Net income |
0.84 | 0.72 | 0.56 | 1.28 | |
Capex/Depreciation |
0.03 | 0.05 | 0.13 | (0.24) | |
Interest Coverage |
14.04 | 14.97 | 20.56 | 5.11 | |
Research and Development Expense of Revenue |
591.92% | 1,044.49% | 340.07% | 135.65% | |
Selling, General and Administrative Expense of Revenue |
371.38% | 459.24% | 194.91% | 60.63% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
142.99% | 209.85% | 94.72% | 33.40% | |
Graham Net Nets |
0.76 | 0.74 | 1.10 | 0.38 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(49.26%) | (36.40%) | (38.83%) | (13.35%) | |
Free Cash Flow Yield |
(38.10%) | (26.72%) | (44.38%) | (11.70%) | |
Revenue per Share |
0.10 | 0.07 | 0.26 | 0.63 | |
Operating CF per Share |
(0.70) | (0.68) | (0.59) | (0.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.70) | (0.68) | (0.59) | (0.64) | |
Cash per Share |
6.74 | 7.44 | 8.43 | 8.66 | |
Shareholders Equity per Share |
6.04 | 6.73 | 7.81 | 8.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.04 | 6.73 | 7.81 | 8.26 | |
Free Cash Flow |
(19.89) | (19.41) | (16.14) | (17.33) | |
Working Capital |
163.63 | 182.51 | 205.07 | 217.50 | |
Capital Expenditures |
0.02 | 0.03 | 0.09 | (0.18) | |
Net Current Asset Value |
144.66 | 162.83 | 184.28 | 191.42 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | (0.02) | (0.01) | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.51 | 7.96 | 4.77 | 19.08 | |
Average Payables |
7.52 | 5.14 | 5.71 | 7.81 | |
Average Assets |
266.79 | 288.60 | 307.61 | 326.50 | |
Average Common Equity |
201.43 | 212.56 | 227.48 | 243.21 |
Columns are period end dates